Results 31 to 40 of about 412,643 (184)
Background The long‐term clinical and biofhemical effects of basal‐bolus insulin treatment with lispro and NPH in dogs with diabetes mellitus are undocumented.
Sharon Kuzi +4 more
doaj +1 more source
Ultra‐Fast Insulin–Pramlintide Co‐Formulation for Improved Glucose Management in Diabetic Rats
Dual‐hormone replacement therapy with insulin and amylin in patients with type 1 diabetes has the potential to improve glucose management. Unfortunately, currently available formulations require burdensome separate injections at mealtimes and have ...
Caitlin L. Maikawa +9 more
doaj +1 more source
Background: Mechanistically, subcutaneous ultra-rapid lispro (URLi) is faster than lispro. Whether this translates into a better post-prandial glucose (PPG) and glycemic control in type-1 diabetes (T1DM) and type-2 diabetes (T2DM) is unclear.
Deep Dutta +3 more
doaj +1 more source
Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report
Introduction Circumscript, progressing lipoatrophy at the insulin injection sites is an unexplained, however rare condition in diabetes mellitus. Case presentation We report a case of severe localised lipoatrophy developing during insulin pump-treatment (
Chantelau Ernst A +3 more
doaj +1 more source
Purpose: To assess the risk of severe hypoglycemia in Turkish patients with type 2 diabetes mellitus (T2DM) starting insulin therapy with premixed insulin analogues alone or in combination with oral antihyperglycemic medications.
Adem Yürümez +7 more
doaj +1 more source
ABSTRACT Aims/Introduction In type 1 diabetes (T1D), insulin requirements and glycemic control may vary across the menstrual cycle. We examined phase‐related differences in insulin requirements, glycemic metrics, and recorded carbohydrate amounts in women using an advanced hybrid closed‐loop (AHCL) system and their associations with menstrual symptoms ...
Eri Takagi +11 more
wiley +1 more source
Management of Diabetes Mellitus with Insulin Lispro
Insulin lispro (Humalog®) is a recombinant human insulin analogue with reversed amino acids at position 28 and 29 on the insulin B-chain (Lys(B28), Pro(B29)).
Masami Tanaka, Hiroshi Itoh
core +1 more source
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj +8 more
wiley +1 more source
Transient Neonatal Diabetes Mellitus in a Very Preterm Infant due to ABCC8 Mutation
Neonatal diabetes mellitus (NDM) is a monogenic form of diabetes occurring within 6 months from birth. NDM can be permanent or transient (TNDM). We report the case of a preterm infant with TNDM due to an ABCC8 mutation identified by next-generation ...
Barbara Piccini +8 more
doaj +1 more source

